TCGA-55-6982-01A-11R-1949-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.460
- ANGIOGENESIS+0.440
- CHOLESTEROL_HOMEOSTASIS+0.420
- PROTEIN_SECRETION+0.410
- COMPLEMENT+0.400
- COAGULATION+0.390
- IL6_JAK_STAT3_SIGNALING+0.360
- ALLOGRAFT_REJECTION+0.340
Top 10 suppressed
- E2F_TARGETS-0.340
- MYC_TARGETS_V2-0.330
- G2M_CHECKPOINT-0.290
- MYC_TARGETS_V1-0.280
- DNA_REPAIR-0.260
- SPERMATOGENESIS-0.220
- OXIDATIVE_PHOSPHORYLATION-0.160
- WNT_BETA_CATENIN_SIGNALING-0.130
- UNFOLDED_PROTEIN_RESPONSE-0.080
- KRAS_SIGNALING_DN-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_V89HGTET | pilocytic astrocytoma | — | 0.917 |
| 2 | BS_MF9X3PKH | low-grade glioma | — | 0.916 |
| 3 | BS_55JW3HFM | Ganglioglioma | — | 0.914 |
| 4 | BS_F8N6CFQE | low-grade glioma | — | 0.912 |
| 5 | SRR8518191 | — | D | 0.911 |
| 6 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.910 |
| 7 | SRR6013590 | — | cohortA1 | 0.902 |
| 8 | BS_Z7Y2466H | pilocytic astrocytoma | — | 0.900 |
| 9 | BS_HC5M8JTC | low-grade glioma | — | 0.899 |
| 10 | BS_014EVM2D | low-grade glioma | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |